Industry Experts

Rachel Liberatore is the President and Chief Scientific Officer at RenBio, a biotechnology company in New York developing a platform technology for durable, DNA-based delivery of monoclonal antibodies and therapeutic proteins. Their lead program is focused on a potent neutralizing antibody against Zika virus, which is being developed for the prevention of Zika virus disease.  Prior to coming to RenBio, Dr. Liberatore used genetic techniques to understand how intrinsic cellular defenses restrict the spreading of retroviruses, including HIV-1. She also studied the elicitation of antiviral antibodies directed at viral envelope proteins. Dr. Liberatore received her bachelor’s degree in Molecular Biology from Princeton University, and her Ph.D. in Cellular, Molecular, and Biomedical Studies from Columbia University.